ARVINAS, INC.: D. E. SHAW & CO, L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
D.E. Shaw & Co., L.P. amended its Schedule 13G stake filing for Arvinas, Inc., according to an SEC filing (accession 0001104659-26-128456). The amendment updates the hedge fund's previously reported beneficial ownership position in the clinical-stage biotech. The filing did not disclose a change in share count or percentage in the headline. Investors watch 13G amendments for signals of institutional conviction in Arvinas, whose pipeline centers on targeted protein degradation.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
D. E. Shaw & Co., L.P., Arvinas, Inc.